Clinical Trial News

Empagliflozin, an SGLT2 inhibitor, is safe and effective for treating heart attack patients, showing kidney-protective benefits and reducing heart failure events regardless of baseline kidney function, according to a Mount Sinai-led study presented at the European Society of Cardiology Congress.

Long-term ixekizumab treatment showed similar efficacy in challenging body areas of psoriasis over 5 years.

Abata Therapeutics' ABA-101, an autologous Treg therapy for progressive MS, received FDA fast track designation. It shows a tolerable safety profile and potential therapeutic effect, aiming to treat progressive MS patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.

BGB-16673 received FDA fast-track designation for R/R CLL/SLL, potentially eligible for accelerated approval. Sonrotoclax combined with zanubrutinib showed improved responses in R/R CLL/SLL. Lurbinectedin vs topotecan data in ES-SCLC explored. Financial toxicity addressed through a tumor board. Clinicians discuss paclitaxel vs docetaxel in HER2-positive breast cancer.

Additional data from SEQUOIA-HCM trial show aficamten improves cardiac remodeling, structure, function, symptoms, and biomarkers in patients with obstructive hypertrophic cardiomyopathy (HCM). Presentations at the European Society of Cardiology Congress 2024 were accompanied by four simultaneous journal publications. Cytokinetics to host a conference call on September 3rd to discuss these findings.

Semaglutide in Ozempic reduces heart failure events by 27% and cardiovascular death by 29% in diabetics with chronic kidney disease, according to a study.

TAVI was superior to surgical aortic valve replacement for reducing death, stroke, or rehospitalisation in women with severe aortic stenosis, according to the RHEIA trial. TAVI reduced rehospitalisations and offered shorter hospital stays, suggesting it could be the preferred treatment option for women with severe aortic stenosis.

Diana Burgess, PhD, presents results of the Learning to Apply Mindfulness to Pain (LAMP) multisite, pragmatic clinical trial, comparing two methods.

The Stop-or-Not Trial found no significant difference in death and major complications at 28 days after noncardiac surgery between continuing and discontinuing renin-angiotensin system (RAS) inhibitor therapy, suggesting both strategies are acceptable. Clinicians should manage RAS inhibitor therapy based on individual patient factors and surgery specifics.

Linvoseltamab, a BCMA bispecific antibody, showed efficacy in relapsed/refractory multiple myeloma with an objective response rate of 70.9%, but requires aggressive supportive care to manage high infection risks, especially in communities without clinical trial experience. The importance of supportive care, including intravenous immunoglobulin, and potentially reducing dosing frequency to mitigate infection risks, was emphasized.